Circle Pharma and Verismo feature in coveted sessions.
ApexOnco Front Page
Recent articles
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
Projects from Chia Tai and Kestrel enter phase 1, along with a bispecific Kelun ADC.
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.
Talapro-3 could help move Talzenna into earlier prostate cancer.
Single, double and even triple-payload ADCs will be presented at the meeting.
